BackPURE Bioscience Overview

PURE Bioscience Total Liabilities

Track PURE Bioscience's total liabilities ($7.4M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$7.40M
↑ 25.99% YoYΔ $1.53M vs prior year quarter

Peer trimmed avg / median

Loading

PURE Bioscience Total Liabilities History

Loading

PURE Bioscience vs. peers: Total Liabilities Comparison

Loading

PURE Bioscience Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

PURE Bioscience (PURE) FAQ

PURE Bioscience (PURE) currently reports a total liabilities of $7.4M as of April 2026. That compares with $5.9M in the prior-year period — up 26.0% year over year. Use the charts on this page to explore PURE Bioscience's total liabilities history and peer comparisons.

PURE Bioscience's total liabilities increased from $5.9M to $7.4M — a 26.0% year-over-year increase (period ending April 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PURE Bioscience reported $7.4M in total liabilities as of April 2026. That compares with $5.9M in the prior-year period — up 26.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $7.4M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for PURE Bioscience, and consider following PURE for alerts when major investors trade the stock.